Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Kaur, Daman Preeta; * | Bucholc, Magdab | Finn, David P.c | Todd, Stephend | Wong-Lin, Kong Fattb | McClean, Paula L.a
Affiliations: [a] Personalised Medicine Centre, School of Medicine, Ulster University, Altnagelvin Hospital, Derry/Londonderry, Northern Ireland, UK | [b] Intelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Derry/Londonderry, Northern Ireland, UK | [c] Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, University of Ireland, Galway, Ireland | [d] Altnagelvin Area Hospital, Western Health and Social Care Trust, Derry/Londonderry, Northern Ireland, UK
Correspondence: [*] Correspondence to: Daman Kaur, Personalised Medicine Centre, School of Medicine, Ulster University, C-TRIC Building, Altnagelvin Hospital, Glenshane Road, Derry/Londonderry, BT47 6SB, Northern Ireland, UK. E-mail: damanpkt93@gmail.com.
Abstract: Background:The Clinical Dementia Rating Scale Sum of Boxes (CDRSOB) score is known to be highly indicative of cognitive-functional status and is regularly employed for clinical and research purposes. Objective:Our aim is to determine whether CDRSOB is consistent with clinical diagnosis in evaluating drug class associations with risk of progression to mild cognitive impairment (MCI) and dementia. Methods:We employed weighted Cox regression analysis on longitudinal NACC data, to identify drug classes associated with disease progression risk, using clinical diagnosis and CDRSOB as the outcome. Results:Aspirin (antiplatelet/NSAID), angiotensin II inhibitors (antihypertensive), and Parkinson’s disease medications were significantly associated with reduced risk of progression to MCI/dementia and Alzheimer’s disease medications were associated with increased MCI-to-Dementia progression risk with both clinical diagnosis and CDRSOB as the outcome. However, certain drug classes/subcategories, like anxiolytics, antiadrenergics, calcium (Ca2+) channel blockers, and diuretics (antihypertensives) were associated with reduced risk of disease progression, and SSRIs (antidepressant) were associated with increased progression risk only with CDRSOB. Additionally, metformin (antidiabetic medication) was associated with reduced MCI-to-Dementia progression risk only with clinical diagnosis as the outcome. Conclusions:Although the magnitude and direction of the effect were primarily similar for both diagnostic outcomes, we demonstrate that choice of diagnostic measure can influence the significance of risk/protection attributed to drug classes and consequently the conclusion of findings. A consensus must be reached within the research community with respect to the most accurate diagnostic outcome to identify risk and improve reproducibility.
Keywords: Alzheimer’s disease, anticoagulants, antidepressants, antihypertensives, CDRSOB, dementia, diagnosis, metformin, mild cognitive impairment, risk factors
DOI: 10.3233/JAD-230456
Journal: Journal of Alzheimer's Disease, vol. 100, no. 2, pp. 631-644, 2024
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl